Constipation: Pathophysiology and current therapeutic approaches

Handbook of Experimental Pharmacology

Volumn 239, Issue , 2017, Pages

  Sharma, Amol ^a   Rao, Satish ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Chronic constipation; Constipation predominant irritable bowel syndrome (IBS C); Dyssynergic defecation; Slow transit constipation

Indexed keywords

CISAPRIDE; ELOBIXIBAT; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MOSAPRIDE; NARONAPRIDE; NON PRESCRIPTION DRUG; PLECANATIDE; PRUCALOPRIDE; TEGASEROD; VELUSETRAG;

ARTICLE; BIOFEEDBACK; CECOSTOMY; COLON RESECTION; CONSTIPATION; DIET; EXERCISE; HUMAN; IRRITABLE COLON; LIFESTYLE MODIFICATION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ABDOMINAL SURGERY; ADVERSE EFFECTS; ANIMAL; CHRONIC DISEASE; CONVALESCENCE; DEFECATION; DRUG EFFECTS; GASTROINTESTINAL MOTILITY; INNERVATION; INTESTINE; INTESTINE INNERVATION; RISK FACTOR; RISK REDUCTION; SURGERY; TREATMENT OUTCOME;

ANIMALS; BIOFEEDBACK, PSYCHOLOGY; CHRONIC DISEASE; CONSTIPATION; DEFECATION; DIET; DIGESTIVE SYSTEM SURGICAL PROCEDURES; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINES; LAXATIVES; RECOVERY OF FUNCTION; RISK FACTORS; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME;

EID: 85018520869     PISSN: 01712004     EISSN: 18650325     Source Type: Book Series    
DOI: 10.1007/164_2016_111     Document Type: Article

References (99)

1. Abdulla H, Yu S, Rattanakovit K, Badger C, Rao SS (2015) Small intestinal bacterial (SIBO) and fungal overgrowth (SIFO): a frequent unrecognized complication of colectomy. AmJGastroenterol 110(Suppl 1s):S995
2. Arebi N, Kalli T, Howson W et al (2011) Systematic review of abdominal surgery for chronic idiopathic constipation. Colorectal Dis 13: 1335-1343
3. Constipation: Pathophysiology and Current Therapeutic Approaches Ashraf W, Park F, Lof J, Quigley EM (1995) Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 9: 639-647
4. Attaluri A, Jackson M, Paulson J, Rao SSC (2010) Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol 105: 1407-1411
5. Attaluri A, Donahoe R, Valestin J, Brown K, Rao SS (2011) Randomized clinical trial: dried plums (prunes) vs. psyllium for constipation. Aliment Pharmacol Ther 33: 822-828
6. Bang CS, Kim JH, Baik GH et al (2015) Mosapride treatment for functional dyspepsia: a metaanalysis. J Gastroenterol Hepatol 30: 28-42
7. Bassil AK, Borman RA, Jarvi EM et al (2008) Activation of prostaglandin EP receptors by lubiprostone in rat and human stomach and colon. Br J Pharmacol 154: 126-135
8. Bassotti G, Iantorno G, Fiorella S, Bustos-Fernandez L, Bilder CR (1999) Colonic motility in man: features in normal subjects and in patients with chronic idiopathic constipation. AmJ Gastroenterol 94: 1760-1770
9. Belsey J, Greenfield S, Candy D, Geraint M (2010) Systemic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther 31: 938-949
10. Bharucha AE, Wald A, Enck P et al (2006) Functional anorectal disorders. Gastroenterology 130: 1510-1518
11. Bharucha AE, Dorn SD, Lembo A et al (2013) American Gastroenterological Association medical position statement on constipation. Gastroenterology 144: 211-217
12. Busby RW, Bryant AP, Bartolini WP et al (2010) Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 649: 328-335
13. Camilleri M (2015) Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions. Gastroenterology 148:483-487
14. Camilleri M, Gores GJ (2015) Therapeutic targeting of bile acids. Am J Physiol Gastrointest Liver Physiol 309: G209-G215
15. Camilleri M, Vazquez-Roque MI, Burton D et al (2007) Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 19: 30-38
16. Camilleri M et al (2010) Wireless pH motility capsule for colonic transit: prospective comparison with radiopaque markers in chronic constipation. Neurogastroenterol Motil 22: 874-882.e233
17. Castro J, Harrington AM, Hughes PA et al (2013) Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3050-monophosphate. Gastroenterology 145: 1334-1346
18. Chang L, Lembo A, Sultan S (2014) American Gastroenterological Association Institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 147: 1149-1172
19. Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE (1995) Mechanisms of constipation in older persons and effects of fibre compared with placebo. J Am Geriatr Soc 43: 666-669
20. Chevalier P, Lamotte M, Joseph A et al (2014) Inpatient costs associated with chronic constipation in Belgium: a retrospective database study. Neurogastroenterol Motil 26: 368-376
21. Chey WD, Camilleri M, Chang L et al (2011) A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 106: 1803-1812
22. Chey WD, Lembo AJ, Lavis BJ et al (2012) Linaclotide for irritable bowel syndrome with constipation: 26-week, randomized, double-blind, placebo-controlled trial to evaluate safety and efficacy. Am J Gastroenterol 107: 1702-1712
23. Chey WD, Webster L, Sostek M et al (2014) Naloxegol for opioid-induced constipation in patients with noncancer pain. N Engl J Med 370: 2387-2396
24. Chey WD, Kurlander J, Eswaran S (2015) Irritable bowel syndrome: a clinical review. JAMA 313: 949-958
25. Chiarioni G, Whitehead WE, Pezza V et al (2006) Biofeedback is superior to laxatives for normal transit constipation due to pelvic floor dyssynergia. Gastroenterology 130: 657-664
26. Coss-Adame E, Rao SSC (2014) Brain and gut interactions in irritable bowel syndrome: new paradigm and new understandings. Curr Gastroenterol Rep 16: 37
27. CrowellMD, ShetzlineMA,Moses PL et al (2004) Enterochromaffin cells and 5-HT signalling in the pathophysiology of disorders of gastrointestinal function. Curr Opin Investig Drugs 5: 55-60
28. Crowell MD, Harris L, Jones MP et al (2005) New insights into the pathophysiology of irritable bowel syndrome: implications for future treatments. Curr Gastroenterol Rep 7: 272-279
29. Cummings JH, Macfarlane GT (1991) The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 70: 443-459
30. Dinning PG, Jones M, Hunt L et al (2011) Factor analysis identifies subgroups of constipation. World J Gastroenterol 17: 1468-1474
31. Dinning PG, Wiklendt L, Maslen L et al (2014) Quantification of in vivo colonic motor patterns in healthy humans before and after a meal revealed by high resolution optic manometry. Neurogastroenterol Motil 26: 1443-1457
32. Erdogan A, Rao SSC, Thiruvalyaru D et al (2016) Randomised clinical trial: mixed soluble/insoluble fibre vs. psyllium for chronic constipation. Aliment Pharmacol Ther 44: 35-44
33. Fenn GC, Wilkinson PD, Lee CE, Akbar FA (1986) A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract 40: 192-197
34. Ford AC, Suares NC (2011) Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systemic review and meta-analysis. Gut 60: 209-218
35. Goldberg M, Li P, Johanson JF et al (2010) Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 32: 1102-1112
36. Herve S et al (2004) Results of 24-h manometric recording of colonic motor activity with endoluminal instillation of bisacodyl in patients with severe chronic slow transit constipation. Neurogastroenterol Motil 16: 397-402
37. Herz MJ, Kahan E, Zalevski S et al (1996) Constipation: a different entity for patients and doctors. Fam Pract 13: 156-159
38. Heymen S, Wexner SD, Vickers D et al (1999) Prospective, randomized trial comparing for biofeedback techniques for patients with constipation. Dis Colon Rectum 42: 1388-1393
39. Higgins PD, Johanson JF (2004) Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 99: 750-759
40. Jarmuz A, Zielinska M, Storr M, Fichna J (2015) Emerging treatments in neurogastroenterology: perspectives of guanylate cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil 27: 1057-1068
41. Kamm MA, Mueller-Lissner S, Wald A et al (2011) Oral bisacodyl is effective and well-tolerated in patients with chronic constipation. Clin Gastroenterol Hepatol 9: 577-583
42. Kassinen A, Krogius-Kurikka L, Makivuokko H et al (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133: 24-33
43. Lee YY, Erdogan A, Rao SS (2013) High resolution and high definition anorectal manometry and pressure topography: diagnostic advance or a new kid on the block? Curr Gastroenterol Rep 15:360
44. Lee-Robichaud H, Thomas K, Morgan J et al (2010) Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 7: CD007570
45. Lees NP, Hodson P, Hill J et al (2004) Long-term results of the antegrade continent enema procedure for constipation in adults. Colorectal Dis 6: 362-368
46. Lembo A, Johanson JF, Parkman HP et al (2011) Long-term safety and effectiveness of lubiprostone, a chloride channel (CIC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 56: 2639-2645
47. Levitt MD, Furne JK, KuskowskiMet al (2006) Stability of human methanogenic flora over 35 years and a review of insights obtained from breath methane measurements. Clin Gastroenterol Hepatol 4: 123-129
48. Longstreth GF, Thompson WG, Chey WD et al (2006) Functional bowel disorders. Gastroenterology 131: 688
49. Lui Z, Sakakibara R, Odaka T et al (2005) Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20: 680-686
50. Lyford GL, He CL, Soffer E et al (2002) Pan-colonic decrease in interstitial cells of Cajal in patients with slow transit constipation. Gut 51: 496-501
51. Manini ML, Camilleri M, Goldberg M et al (2010) Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 22: 42-49
52. Mayer EA, Tillisch K (2011) The brain-gut axis in abdominal pain syndromes. Annu Rev Med 62: 381-396
53. Mertz H, Naliboff B, Munakata J et al (1995) Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 109: 40-52
54. Miner PB et al (2014) Plecanatide, a novel uroguanylin analog: a 12-week, randomized, doubleblind, placebo-controlled, dose ranging trial to evaluate efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C). Am J Gastroenterol 109: S541
55. Mugie SM, Benninga MA, DiLorenzo C (2011) Epidemiology of constipation in children and adults: a systemic review. Best Pract Res Clin Gastroenterol 25: 3-18
56. Papachrysostomou M, Smith AN (1994) Effects of biofeedback on obstructive defecation -reconditioning of the defecation reflex? Gut 35:242-245
57. Pare P, Ferrazzi S, Thompson D et al (2001) An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 96: 3130-3137
58. Pemberton JH, Rath DM, Ilstrup DM (1991) Evaluation and surgical treatment of severe chronic constipation. Ann Surg 214: 403-413
59. Pimental M, Lin HC, Enayati P et al (2006) Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. Am J Physiol Gastrointest Liver Physiol 290: G1089-G1095
60. Pimental M, Gunsalus RP, Rao SSC et al (2012) Methanogens in human health and disease. Am J Gastroenterol Suppl 1: 28-33
61. Posserud I, Stotzer P, Björnsson E, Abrahamsson H, Simrén M (2007) Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 56: 802-808
62. Preston DM, Lennard-Jones JE (1986) Severe colonic constipation of young women: "idiopathic slow transit constipation". Gut 27: 41-48
63. Quigley EMM (2011) Cisapride: what can we learn from the rise and fall of a prokinetic? J Dig Dis 12:147-156
64. Quigley EMM, Neshatian L (2016) Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother 17: 501-511
65. Raizada V, Bhargava V, Karsten A, Mittal RK (2011) Functional morphology of anal sphincter complex unveiled by high definition anal manometry and three dimensional ultrasound imaging. Neurogastroenterol Motil 23: 1013-1019.e460
66. Rao SS (2008) Dyssynergic defecation and biofeedback therapy. Gastroenterol Clin North Am 37: 569-586
67. Rao SS, Enck P, Loening-Baucke V (1997) Biofeedback therapy for defecation disorders. Dig Dis 15(Suppl 1):78-92
68. Rao SS, Welcher KD, Leistikow JS (1998a) Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol 93: 1042-1050
69. Rao SS, Ozturk R, De Ocampo S, Stessman M (1998b) Pathophysiology and role of biofeedback therapy in solitary rectal ulcer syndrome. Am J Gastroenterol 101: 613-618
70. Rao SS, Tuteja AK, Vellema T et al (2004) Dyssynergic defecation: demographics, symptoms, stool patterns, and quality of life. J Clin Gastroenterol 38: 680-685
71. Rao SS, Ozturk R, Lain L (2005a) Clinical utility of diagnostic tests for constipation in adults: a systemic review. Am J Gastroenterol 100: 1605-1615
72. Rao SS, Kinkade K, Miller MJ et al (2005b) Randomized controlled trial of long term outcome of biofeedback therapy (BT) for dyssynergic defecation. Am J Gastroenterol 100: 386
73. Rao SSC, Kavlock R, Rao S (2006) Influence of body position and stool characteristics on defecation in humans. Am J Gastroenterol 101: 2790-2796
74. Rao SS et al (2007a) Psychological profiles and quality of life differ between patients with dyssynergia and those with slow transit constipation. J Psychosom Res 63: 441-449
75. Rao SS, Seaton K, MillerMet al (2007b) Randomized controlled trial of biofeedback, sham feedback, and standard therapy for dyssynergic defecation. Clin Gastroenterol Hepatol 5: 331-338
76. Rao S, Lembo AJ, Shiff SJ et al (2012) A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 107: 1714-1724
77. Rao SS, Yu S, Fedewa A (2015) A systemic review: dietary fibre and FODMAP-restricted diet in the management of constipation and irritable bowel syndrome. Aliment Pharmacol Ther 41: 1256-1270
78. Rattanakovit K, Rao SS, Amieva M, Mack A, Dewitt A (2015) Dyssynergia or no dyssynergia: phenotypic categorization of constipated patients with high-resolution anorectal manometry (HRAM). Am J Gastroenterol 110(Suppl 1s):S593
79. Ravi K et al (2010) Phenotypic variation of colonic motor functions in chronic constipation. Gastroenterology 138: 89-97
80. Reiner CS et al (2011) MR defecography in patients with dyssynergic defecation: spectrum of imaging findings and diagnostic value. Br J Radiol 84: 136-144
81. Remes-Troche JM, Rao SS (2006) Diagnostic testing in patients with chronic constipation. Curr Gastroenterol Rep 8: 416-424
82. Ringel Y, Carroll IM (2009) Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest Endosc Clin N Am 19:141-150
83. Sachdev AH, Pimental M (2012) Antibiotics for irritable bowel syndrome: rationale and current evidence. Curr Gastroenterol Rep 14: 439-445
84. Sethi S, Mikami S, Leclair J et al (2014) Inpatient burden of constipation in the United States: an analysis of national trends in theUnited States from1997 to 2010. Am J Gastroenterol 109:250-256
85. Shepherd SJ, Lomer MC, Gibson PR (2013) Short-chain carbohydrates and functional gastrointestinal disorders. Am J Gastroenterol 108: 707-717
86. Shin A, Camilleri M, Kolar G et al (2014) Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 39: 239-253
87. Simren M, Bajor A, Gillberg PG et al (2011) Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation-a double-blind study. Aliment Pharmacol Ther 34: 41-50
88. Singh G, Lingala V, Wang H et al (2007) Use of health care resources and cost of care for adults with constipation. Clin Gastroenterol Hepatol 5: 1053-1058
89. Singh S, Heady S, Coss-Adame E, Rao SS (2013) Clinical utility of colonic manometry in slowtransit constipation. Neurogastroenterol Motil 25: 487-495
90. Soares AC, Lederman HM, Fagundes-Neto U (2005) Breath methane associated with slow colonic transit time in children with chronic constipation. J Clin Gastroenterol 39: 512-515
91. Sommers T, Corban C, Sengupta N et al (2015) Emergency department burden of constipation in the United States from 2006 to 2011. Am J Gastroenterol 110: 572-579
92. Spiller R, Lam C (2012) An update on post-infectious irritable bowel syndrome: role of genetics, immune activation, serotonin and altered microbiome. J Neurogastroenterol Motil 18: 258-268
93. Stephen AM, Cummings JH (1980) Mechanism of action of dietary fibre in the human colon. Nature 284: 283-284
94. Suares NC, Ford AC (2011) Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systemic review and meta-analysis. Am J Gastroenterol 106: 1582-1591
95. Tack J, Camilleri M, Chang L et al (2012) Systemic review: cardiovascular safety profile of 5HT4 agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 35:745-767
96. Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Gut 45: 1143-1147
97. Tomlin J, Read NW (1988) The relation between bacterial degradation of viscous polysaccharides and stool output in human beings. Br J Nutr 60: 467-475
98. Xiao ZL, Pricolo V, Biancani P, Behar J (2005) Role of progesterone signalling in the regulation of G-protein levels in female chronic constipation. Gastroenterology 128: 667-675
99. Yu SW, Rattanakovit K,Mack A, Rao SS (2015) Is gastroparesis a pan-enteric neuropathic disorder: investigation with wireless motility capsule? Gastroenterology 148(Suppl 1):S516-S517